TY - JOUR
T1 - Cancer treatment with kinase inhibitors
T2 - What have we learnt from imatinib?
AU - Ross, D. M.
AU - Hughes, T. P.
PY - 2004/1/12
Y1 - 2004/1/12
N2 - Over the past few years, a number of anticancer drugs have been developed that specifically target kinases known to be oncogenic. The leading drug in this area is imatinib mesylate, which targets ABL, KIT and PDGFR. It has been remarkably effective in the treatment of chronic myeloid leukaemia, although resistance remains a significant problem. From the imatinib experience in this setting, we present some principles of kinase inhibition that may have more general applicability in targeted anticancer therapy. It is clear that the identification of appropriate targets (activated kinases) and monitoring levels of response (to recognise emerging resistance) are essential to optimise clinical management.
AB - Over the past few years, a number of anticancer drugs have been developed that specifically target kinases known to be oncogenic. The leading drug in this area is imatinib mesylate, which targets ABL, KIT and PDGFR. It has been remarkably effective in the treatment of chronic myeloid leukaemia, although resistance remains a significant problem. From the imatinib experience in this setting, we present some principles of kinase inhibition that may have more general applicability in targeted anticancer therapy. It is clear that the identification of appropriate targets (activated kinases) and monitoring levels of response (to recognise emerging resistance) are essential to optimise clinical management.
UR - http://www.scopus.com/inward/record.url?scp=0842265178&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6601507
DO - 10.1038/sj.bjc.6601507
M3 - Short survey
C2 - 14710199
AN - SCOPUS:0842265178
VL - 90
SP - 12
EP - 19
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 1
ER -